<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126384</url>
  </required_header>
  <id_info>
    <org_study_id>INSERM-C12-10</org_study_id>
    <secondary_id>2013-000850-23</secondary_id>
    <nct_id>NCT02126384</nct_id>
  </id_info>
  <brief_title>Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response</brief_title>
  <acronym>PNEUMOVACB</acronym>
  <official_title>Analysis of the Response of Healthy Adults to a 23-valent Pneumococcal Polysaccharide Vaccine to Identify the B Cell Subsets Responsible for the Production of IgM, IgG2 and IgA Anti-pneumococcal Capsular Polysaccharides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which B lymphocytes subsets are responsible for the&#xD;
      production of IgM, IgG2 and IgA anti-pneumococcal capsular polysaccharides after vaccination&#xD;
      with a 23-valent pneumococcal polysaccharide vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to identify which specific B cell subset(s) is/are responsible for&#xD;
      the production of protective IgM, IgG2 and IgA anti-pneumococcal capsular polysaccharides&#xD;
      (capPS) in response to immunization of healthy individuals with the Pneumovax, a prototypical&#xD;
      T-independent type 2 vaccine. In other words, from which B cells are IgM, G2 and A-secreting&#xD;
      plasma cells derived? To address this question, it will be taken advantage of the unique Ig&#xD;
      heavy chain VDJ signature expressed by each B cell clone and the strategy will rely on the&#xD;
      search of clonal filiations between plasmablasts (PB)/plasma cells (PC) and different B cell&#xD;
      subpopulations. Therefore, healthy individuals will be vaccinated with Pneumovax, and blood&#xD;
      samples will be collected at day 0, 7, 14, 28 and 56. Starting from these blood samples,&#xD;
      different B cells subsets (in particular IgM+IgD+CD27+ and switched memory IgM-IgD-CD27+ B&#xD;
      cells) and the PB/PC peaking at day 7 after vaccination will be isolated by cell sorting.&#xD;
      CapPS-secreting PB cannot be specifically isolated, but the investigators assume that they&#xD;
      will represent the majority of the isolated PB/PC at the peak of the response. Thus, day&#xD;
      7-PB/PC will be sorted both in bulk or as single cells in 96-well PCR plates. RNA will be&#xD;
      extracted from bulk sorted PB/PC, and VDJ-µ, -alpha and -gamma Ig transcripts will be&#xD;
      amplified by RT-PCR and analyzed by the H-CDR spectratyping method in order to identify the&#xD;
      sequence of dominant VDJ signatures that most probably correspond to anti-capPS-secreting&#xD;
      cells. In parallel, for each PB/PC single cell, Ig heavy and corresponding Ig light chain&#xD;
      gene transcripts will be amplified by nested RT-PCR, sequenced, and provided that the heavy&#xD;
      chain contains a dominant VDJ signature, they will be cloned into eukaryotic expression&#xD;
      vectors to produce monoclonal human Abs. The recombinant antibodies will then be tested for&#xD;
      reactivity against capPS from the vaccine by ELISA. When VDJ signatures of capPS will be&#xD;
      validated, with this powerful molecular tool, the investigators will look for the presence of&#xD;
      these signatures through VDJ-specific PCR on cDNA prepared from the different B cell subsets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2014</start_date>
  <completion_date type="Actual">April 5, 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the precursor of B lymphocytes</measure>
    <time_frame>day 7</time_frame>
    <description>On vitro measure of blood mononuclear cell populations by cell sorting at day 7 to identify the clonal progeny of the secreting B lymphocyte precursor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of serum anti-capsular polysaccharide antibody titers</measure>
    <time_frame>day 0, day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pneumococcal Diseases</condition>
  <arm_group>
    <arm_group_label>pneumovax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, open label pneumovax vaccination of healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pneumovax vaccination</intervention_name>
    <description>vaccination</description>
    <arm_group_label>pneumovax</arm_group_label>
    <other_name>pneumovax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  aged 18 to 40 y&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no documented primary immunodeficiency&#xD;
&#xD;
          -  no splenectomy&#xD;
&#xD;
          -  no functional/congenital asplenia,&#xD;
&#xD;
          -  no pneumococcal infections within the last 5 years before enrolment into the research&#xD;
             protocol&#xD;
&#xD;
          -  no vaccinations with the 23-valent pneumococcal polysaccharide vaccine or the 7- or&#xD;
             13-valent conjugate-polysaccharide vaccines within the last 5 years before enrolment&#xD;
             into the research protocol&#xD;
&#xD;
          -  no other vaccination within 1 month before enrolment into the research protocol&#xD;
&#xD;
          -  fever, current antibiotic treatment&#xD;
&#xD;
          -  any chronic or inflammatory disease&#xD;
&#xD;
          -  any immunosuppressive treatment&#xD;
&#xD;
          -  hyper-responsiveness to one component of the Pneumovax vaccine&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra WELLER, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la santé et de la recherché Médicale (INSERM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunology</keyword>
  <keyword>human</keyword>
  <keyword>B-lymphocytes subsets</keyword>
  <keyword>Antibody-Producing Cells</keyword>
  <keyword>23 valent pneumococcal capsular polysaccharide vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

